Licence applications
Submitted through the ERS Express Licensing Portal
Sample data
Total
6
applications
Awaiting review
3
submitted or in review
Info requested
1
blocked on applicant
Early Access
2
reduced-cost entry
Applications
Newest first — select a row for detail
| Reference | Organisation | Country | Type | Status |
|---|---|---|---|---|
| EXP-2026-0143 | Nordica Therapeutics | Sweden | Express | In review |
| EAX-2026-0031 | Bramble Bio | Czechia | Early Access | Submitted |
| EXP-2026-0142 | Meridian Crop Science | India | Express | Info requested |
| EXP-2026-0139 | Clonmel Diagnostics | Ireland | Express | Approved |
| EXP-2026-0137 | Ruhr Biologics | Germany | Express | In review |
| EAX-2026-0029 | Anatolia Gene Labs | Türkiye | Early Access | Declined |
Nordica Therapeutics
EXP-2026-0143 · Dr Elena Rossi
In review
- Licence type
- Express Licence
- Field of use
- Internal research — oncology target discovery
- Country
- Sweden
- Revenue band
- €1m–€5m
- Headcount
- 24
- Submitted
- 27 July 2026
- Summary
- Series A biotech using CRISPR/Cas9 for knockout screens in solid-tumour models. Requests standard Express terms, no manufacturing rights.
Ask the assistant to assess this application — it foreshadows the License Portal Engine on the AI Vision roadmap.